Can a blood patch or talc seal a collapsed lung faster?
NCT ID NCT06883188
First seen Sep 04, 2026 · Last updated Sep 04, 2026
Summary
This pilot trial tests whether a larger study is feasible by comparing two treatments for persistent air leaks in people with secondary spontaneous pneumothorax, a collapsed lung that occurs with underlying lung disease. Participants receive either talc powder or their own blood injected into the chest cavity to seal the leak. The main goal is to see if enough eligible patients enroll and complete follow-up, while also measuring how quickly the air leak stops and whether the chest drain can be removed.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- talc powder or the patient's own venous blood, both given into the chest cavity to seal air leaks
- What this could lead to
- If this pilot succeeds, it could point to a preferred, less invasive way to stop persistent air leaks and avoid surgery in people with secondary spontaneous pneumothorax.
- What could go wrong
- This is a small feasibility study with only 30 participants, so results may not apply broadly. Both treatments carry risks like chest drain blockage or pleural infection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2/3
Runs two stages together: whether the treatment works, then large-scale confirmation.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Nov 2026
An estimate. Start dates often move.
- Expected to finish
-
Mar 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18 years or older * Radiographically proven pneumothorax and underlying lung disease (either pre-existing or shown in diagnostic imaging at presentation) * Spontaneous onset of pneumothorax, not related to trauma or iatrogenic procedure * SSP with air leak persists for ≥3 days after the first radiographic evidence of pneumothorax * Intend to administer talc or autologous blood patch therapy (ABPT) to stop the air leak as the next step of treatment Exclusion Criteria: * A chest drain size smaller than Fr 12 * Bilateral pneumothorax * Impaired blood clotting, including baseline INR \> 1.5, platelet \< 150 x 10\^9/L, use of therapeutic dose anticoagulant or dual-antiplatelet agents * Active or recent (within 6 weeks) pleural infection * Septicaemia or active extrapleural infection (e.g. pneumonia) * Use of long-term systemic corticosteroids or immunosuppressant * Previously received talc or ABPT to the ipsilateral pleural space for the current episode of pneumothorax * Known sensitivity to talc * Has had a previous pneumonectomy (either on the same or contralateral side) * Patients who are pregnant or lactating (females of childbearing potential must have a negative pregnancy test before randomisation) * Expected survival of less than three months from a different pathology to this pneumothorax (e.g. metastatic malignancy) * Cognitively impaired and physically unable to follow the turning procedure during intrapleural procedure, or at risk of self-removing chest drain * Inability to give informed consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pneumothorax spontaneous secondary are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.